Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AEON Biopharma, Inc. (AEON)

AEON Biopharma furnishes October 2026 corporate presentation on ABP-450 development plans

Neutral Impact 2 of 5 other Written later

AEON Biopharma made available a corporate presentation dated October 2026 on its investor relations website on October 23, 2026, and furnished it as Exhibit 99.1 under Item 7.01 of Form 8-K. The filing contains no financial results or guidance; the presentation outlines the company's plan for ABP-450 as a potential biosimilar alternative to BOTOX and states that the product has not been approved by the FDA for any therapeutic indication.

Key points

  • Presentation dated October 2026, made available on the company website October 23, 2026, and furnished as Exhibit 99.1
  • Presentation cites a $3.5 billion U.S. therapeutic botulinum toxin market in 2026, projected to reach $5.1 billion by 2031 per Clarivate
  • IND submission for the CMAP pharmacodynamic study planned for Q4 2026, with study initiation expected in Q1 2027
  • Presentation states ABP-450 has not been approved by the FDA for any therapeutic indication

The filing

CompanyAEON Biopharma, Inc. (AEON)
Form8-K, current report
Filed with the SECOct 23, 2026, 4:15 PM ET
Accession number0001837607-26-000071

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.